AbbVie and Scripps Research announce collaboration to develop a broad range of new therapeutics

Learn more

Our journey of impact

Come with us as we remember where we’ve been, and look forward to where we’re going.

Learn more

Latest news

If you are a member of the news media and have questions or need additional information, please contact our communications team.

Jan 15, 2020

Supporting Relief Efforts: Australian Bushfires

Jan 14, 2020

New Head-to-Head Phase 3 Data Show SKYRIZI™ (risankizumab) Superior to Cosentyx® (secukinumab) Across Primary and All Ranked Secondary Endpoints in Adults with Moderate to Severe Plaque Psoriasis at 52 Weeks

Jan 13, 2020

AbbVie to Host Fourth-Quarter and Full-Year 2019 Earnings Conference Call

Jan 08, 2020

AbbVie Announces Leadership Team and Creation of New Business, Allergan Aesthetics, Upon Completion of Acquisition
Read More

You must be logged in to view this item.

This area is reserved for members of the news media. If you qualify, please update your user profile and check the box marked "Check here to register as an accredited member of the news media". Please include any notes in the "Supporting information for media credentials" box. We will notify you of your status via e-mail in one business day.

YOU ARE ABOUT TO LEAVE FOR A 3RD PARTY WEBSITE

Notice

The "Yes" link below will take you out of the AbbVie family of websites.

Links which take you out of the AbbVie worldwide websites are not under the control of AbbVie, and AbbVie is not responsible for the contents of any such site or any further links from such site. AbbVie is providing these links to you only as a convenience and the inclusion of any link does not imply endorsement of the linked site by AbbVie.

The Internet site that you have requested may not be optimized to your screen size.

Do you wish to leave this site?